Drug Profile


Alternative Names: BRL 61063; HEP 688

Latest Information Update: 13 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Antivirals; Xanthines
  • Mechanism of Action Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Viral infections

Most Recent Events

  • 13 May 2003 Cipamfylline is no longer licensed to LEO Pharma
  • 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Canada (Topical)
  • 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top